38 completed, 26 recruiting, 15 active not recruiting, 8 not yet recruiting. 39 Phase 2, 34 Phase 3, 24 Phase 1, 4 Phase 4.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 39 | Completed 13, Active not recruiting 7, Recruiting 7, Not yet recruiting 6, Terminated 3, Withdrawn 2, Enrolling by invitation 1 |
| Phase 3 | 34 | Completed 11, Recruiting 9, Active not recruiting 5, Terminated 4, Enrolling by invitation 2, Not yet recruiting 2, Withdrawn 1 |
| Phase 1 | 24 | Completed 17, Recruiting 4, Active not recruiting 2, Not yet recruiting 1 |
| Phase 4 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
Follow argenx: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC - Autoimmune Encephalitis (AE) | Phase 2 | Not yet recruiting | argenx | 170 | 2027-04-01 | 2026-09-22 |
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Empasiprubart IV, Empasiprubart Placebo IV, Intravenous immunoglobulin (IVIg) - Guillain-Barré Syndrome (GBS) | Phase 2 | Not yet recruiting | argenx | 63 | 2026-12-01 | 2026-09-25 |
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Not yet recruiting | argenx | 120 | 2026-10-15 | 2026-10-16 |
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Not yet recruiting | argenx | 6 | 2026-09-01 | 2026-06-10 |
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
Adimanebart IV, Placebo IV - Congenital Myasthenic Syndrome, CMS | Phase 3 | Not yet recruiting | argenx | 105 | 2026-09-01 | 2026-10-19 |
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
efgartigimod PH20 SC, Placebo PH20 SC - Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensory Neuropathies | Phase 2 | Not yet recruiting | argenx | 75 | 2026-08-14 | 2026-08-12 |
A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
Empasiprubart IV - Multifocal Motor Neuropathy (MMN) | Phase 1 | Recruiting | argenx | 60 | 2026-07-27 | 2026-09-24 |
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-10-16 |
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI - Healthy Volunteer, Healthy Adult Participants | Phase 1 | Completed | argenx | 32 | 2026-06-19 | 2026-10-14 |
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants
Adimanebart IV, Adimanebart SC - formulation A, Adimanebart SC - formulation B - Healthy Volunteers (HV), Healthy Volunteer | Phase 1 | Recruiting | argenx | 52 | 2026-06-12 | 2026-06-29 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
efgartigimod PH20 SC, Placebo PH20 SC - Graves Disease | Phase 3 | Recruiting | argenx | 230 | 2026-06-10 | 2026-10-16 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Efgartigimod PH20 SC, Placebo PH20 SC - Graves' Disease, Graves Disease | Phase 3 | Recruiting | argenx | 230 | 2026-06-10 | 2026-10-16 |
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
empasiprubart SC AI, empasiprubart IV - Healthy Volunteers | Phase 1 | Recruiting | argenx | 130 | 2026-03-16 | 2026-05-28 |
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
Generalized Myasthenia Gravis (gMG), gMG | | Recruiting | argenx | 100 | 2026-02-25 | 2026-05-19 |
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
ARGX-124, Placebo - Healthy Volunteers | Phase 1 | Recruiting | argenx | 104 | 2026-01-26 | 2026-03-06 |
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Efgartigimod IV, Empasiprubart IV - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis | Phase 2 | Recruiting | argenx | 70 | 2025-12-19 | 2026-09-24 |
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Efgartigimod IV, Empasiprubart IV, Placebo IV - Myasthenia Gravis, MG | | Recruiting | argenx | 70 | 2025-12-19 | 2026-10-16 |
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
ARGX-119 IV, Placebo IV - Spinal Muscular Atrophy (SMA) | Phase 2 | Recruiting | argenx | 60 | 2025-12-19 | 2026-10-08 |
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
Showing 20 of 100. Sign in to see all of them.
Conditions studied
Myasthenia Gravis (18) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (9) · Purpura, Thrombocytopenic, Idiopathic (9) · Leukemia, Myeloid, Acute (4) · Dermatomyositis (3) · Myasthenic Syndromes, Congenital (3) · Myositis (3) · Neoplasms (3) · Pemphigus (3) · Antisynthetase syndrome (2) · Glomerulonephritis (2) · Graves Disease (2) · Graves Ophthalmopathy (2) · Guillain-Barre Syndrome (2) · Kidney Diseases (2)
Interventions
efgartigimod alfa (26) · Azacitidine (4) · Immunoglobulins, Intravenous (4) · Prednisone (4) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · ARGX-111 (1) · venetoclax (1)
Countries
United States (59) · Germany (46) · Italy (45) · Spain (45) · Poland (42) · France (39) · Belgium (38) · United Kingdom (35) · Netherlands (34) · Canada (31) · Japan (30) · Georgia (25) · Austria (23) · Czechia (23) · Hungary (23)
Top investigators
Antonio Guglietta, MD (3) · Clayton Smith, MD (2) · Adrian Newland (1) · Ahmad Awada, MD (1) · Anastasia Vishnevetsky, MD, MPH (1) · Chafic Karam, MD (1) · Colin Quinn, MD (1) · Karolin Trautmann-Grill, Dr. med. (1) · Matt P Marinkovich, MD (1) · Patrick Dupuy, MD (1) · Sabine Coppieters, MD (1)
Results publications
PMID 34146511, PMID 37914483, PMID 39636455, PMID 24492296, PMID 30040076, PMID 31821591, PMID 32601337, PMID 34608631, PMID 35663943, PMID 37093350, PMID 37778358, PMID 38205888, PMID 38318236, PMID 39068745, PMID 39304241, PMID 41224659, PMID 41517964, PMID 41943179, PMID 41997805, PMID 42183242, PMID 42234197, PMID 42551446, PMID 42678488, PMID 42689432, PMID 42699831
NIH funding
2025 (9), 2019 (8), 2023 (8), 2016 (3), 2018 (2), 2017 (1)